Cargando…

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population

BACKGROUND: Galcanezumab is a monoclonal antibody acting against the calcitonin gene‐related peptide approved for the preventive treatment of migraine. The aim of this article is to explore its effectiveness and safety of galcanezumab in chronic migraine (CM) with medication overuse‐headache (MOH)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerzoni, Simona, Baraldi, Carlo, Castro, Flavia Lo, Cainazzo, Maria Michela, Pani, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275517/ https://www.ncbi.nlm.nih.gov/pubmed/37208838 http://dx.doi.org/10.1002/brb3.2799

Ejemplares similares

Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2017)

Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2018)

Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication–overuse headache
por: Pellesi, Lanfranco, et al.
Publicado: (2019)

Predictors of response to erenumab after 12 months of treatment
por: Baraldi, Carlo, et al.
Publicado: (2021)

P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse
por: Guerzoni, Simona, et al.
Publicado: (2015)

Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
por: Baraldi, Carlo, et al.
Publicado: (2021)

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
por: Pensato, Umberto, et al.
Publicado: (2022)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
por: Lo Castro, Flavia, et al.
Publicado: (2021)

Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal
por: Baraldi, Carlo, et al.
Publicado: (2017)

Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

Clinical Evidence of Cannabinoids in Migraine: A Narrative Review
por: Lo Castro, Flavia, et al.
Publicado: (2022)

Galcanezumab for migraine
Publicado: (2020)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
por: Krymchantowski, Abouch V., et al.
Publicado: (2023)

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
por: Mo, Heejung, et al.
Publicado: (2022)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022)

Predictors of galcanezumab response in a real-world study of Korean patients with migraine
por: Kim, Seung Ae, et al.
Publicado: (2023)

Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy
por: Lupi, Chiara, et al.
Publicado: (2019)

Basal cutaneous pain threshold in headache patients
por: Zappaterra, Maurizio, et al.
Publicado: (2011)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
por: Kashiwagi, Kenta, et al.
Publicado: (2023)

Chronic migraine plus medication overuse headache: two entities or not?
por: Negro, Andrea, et al.
Publicado: (2011)

Withdrawal failure in patients with chronic migraine and medication overuse headache
por: D’Amico, Domenico, et al.
Publicado: (2021)

Medication Overuse Headaches among Children—The Contribution of Migraine and TTH
por: Genizi, Jacob, et al.
Publicado: (2023)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
por: Pellesi, Lanfranco, et al.
Publicado: (2020)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache
por: Bellei, Elisa, et al.
Publicado: (2015)

P060. Vitamin D deficiency in episodic migraine, chronic migraine and medication-overuse headache patients
por: Iannacchero, Rosario, et al.
Publicado: (2015)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Temperament and character profiles of patients with chronic migraine and medication-overuse headache
por: Watanabe, Y, et al.
Publicado: (2013)

Migraine-specific quality of life questionnaire and relapse of medication overuse headache
por: Caproni, Stefano, et al.
Publicado: (2015)

Risk of medication overuse headache across classes of treatments for acute migraine
por: Thorlund, Kristian, et al.
Publicado: (2016)

Effects of smartphone overuse on headache, sleep and quality of life in migraine patients
por: Demir, Yasemin P., et al.
Publicado: (2019)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Impact of continuing or quitting smoking on episodic cluster headache: a pilot survey
por: Ferrari, Anna, et al.
Publicado: (2013)

Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache
por: Bellei, Elisa, et al.
Publicado: (2013)

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020)

Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
por: Ornello, Raffaele, et al.
Publicado: (2020)

Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
por: Silvestro, Marcello, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1s186k1gjmgk9rcjdiuhsa7i9p